Arq. Bras. Cardiol. 2019; 112(5): 706
October issue of 2012, vol. 99(4), pages 1-10
DOI: 10.5935/abc.20190091
October issue of 2012, vol. 99(4), pages 1-10
149
How to cite this article
. October issue of 2012, vol. 99(4), pages 1-10. Arq. Bras. Cardiol. 2019;112(5):706.
, . October issue of 2012, vol. 99(4), pages 1-10. Arq. Bras. Cardiol., v. 112, n. 5, p. 706-706, May. 2019.
, (2019). October issue of 2012, vol. 99(4), pages 1-10. Arq. Bras. Cardiol., 112(5), 706-706.
, . October issue of 2012, vol. 99(4), pages 1-10. Arq. Bras. Cardiol. [online]. 2019, vol. 112, n. 5, [cited 2025-09-09], pp.706-706. Available from: <https://abccardiol.org/en/article/october-issue-of-2012-vol-994-pages-1-10/>. ISSN 0066-782X.
Figure 1
Dyslipidemia as a central element in atherosclerotic cardiovascular disease. ASCVD: atherosclerotic cardiovascular disease; LDL-C: low-density lipoprotein cholesterol. Limitations of statin-based therapy (non-exhaustive) include suboptimal LDL-C goal attainment, statin-associated adverse effects that may affect adherence, and potential drug interactions. Residual risk reflects the involvement of multiple underlying pathways.